Repotrectinib

Chemical formula: C₁₈H₁₈FN₅O₂  Molecular mass: 355.144 g/mol  PubChem compound: 135565923

Therapeutic indications

Repotrectinib is indicated for:

ROS1-positive non-small cell lung cancer

Population group: only adults (18 years old or older)

Repotrectinib is indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion-positive solid tumors

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Repotrectinib is indicated for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that:

  • have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion,
  • are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and
  • have progressed following treatment or have no satisfactory alternative therapy.

This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Repotrectinib is contraindicated in the following cases:

Lactation

Lactation

Strong CYP3A inhibitors, moderate CYP3A inhibitors

at least one of
Strong CYP3A4 inhibitors
Cytochrome P-450 CYP3A5 strong inhibitors
Moderate CYP3A4 inhibitors
Cytochrome P-450 CYP3A5 moderate inhibitors

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL/PLR) 2024: AUGTYRO Capsule
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈